⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Dupilumab

دوپیلومب

⚠ Unverified

🧴 DermatologicalsAnti-IL-4Rα antibody

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Use with caution 👶 Children:Use with caution 👴 Older adults:No specific problem stated 🇮🇷 Registered in Iran ⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA761055 ATC D11AH05

Market / country: 🇺🇸 USA

Dupixent (US)

🧮 Dose calculator

Disease / regimen

Atopic dermatitis (eczema) · Regimen source: FDA Dupixent · 2.3

⛔ Initial 600 mg (two 300 mg injections), then 300 mg SC every 2 weeks (not daily). Children ≥6 months: per label weight table. FDA Dupixent · 2.3

🛡️ Safety & information

Contraindications

⛔ Hypersensitivity to dupilumab or its excipients. FDA Dupixent · 4

Warnings

• Conjunctivitis and keratitis; eosinophilic conditions; do not stop steroids abruptly; no live vaccines. FDA Dupixent · 5

Formulations

300 mg/2 mL (and 200 mg/1.14 mL) pen or syringe — injection 🇺🇸 USA FDA Dupixent · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Dupixent · 8.1
“Risk Summary Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.”
🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Dupixent · 8.2
“Risk Summary There are no data on the presence of dupilumab in human milk, the effects on the breastfed infant, or the effects on milk production.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Dupixent · 8.4
“Atopic Dermatitis The safety and effectiveness of DUPIXENT have been established in pediatric patients 6 months of age and older with moderate-to-severe AD, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Dupixent · 8.5
“No overall differences in safety or effectiveness of DUPIXENT have been observed between subjects 65 years of age and older and younger adult subjects.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)BLA761055
DailyMed (FDA label)FDA Dupixent
MedlinePlus (NIH)Dupilumab Injection
WHO ATC/DDDD11AH05
Darooyab (Iran)Dupilumab

🇮🇷 Registered in Iran Darooyab · G-5363/Dupilumab

Dosage forms with Iranian generic codes, per Darooyab.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Dupixent · 3 FDA Dupixent · 2.3 FDA Dupixent · 2 FDA Dupixent · 2.8 FDA Dupixent · 4 FDA Dupixent · 5 FDA Dupixent · SPL approval / marketing category FDA Dupixent · 8.1 FDA Dupixent · 8.2 FDA Dupixent · 8.4 FDA Dupixent · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-5363/Dupilumab
Clinical review⚠ Unverified